Investigational drug · Phase 2
CART84
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Acute Myeloblastic Leukaemia, Leukemia, T-Cell.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "CART84"
First trial start
2026
Feb 4, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CART84", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Myeloblastic Leukaemia
- Leukemia, T-Cell
Approved drugs for the same conditions: Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "CART84" as an intervention, largest first.
Gyala TherapeuticsIndustry
NCT07471789 · 33 participants (planned) · Start Feb 4, 2026 · Primary completion May 31, 2029
Drug: CART84 · For: Acute Myeloblastic Leukaemia; Leukemia, T-Cell
Sites: Barcelona, Spain; Valencia, Spain
Newest research
PubMed records naming it or its code names, newest first.
- Impact of IL-21 on CAR T-cell manufacturing: phenotypic, metabolic, and functional outcomes.
Val-Casals M, Altuna A, Pérez-Amill L, et al. · Front Immunol 2026
- A novel chimeric antigen receptor T-cell therapy targeting CD84 for the treatment of acute myeloid and T-cell lymphoblastic leukemias.
Pérez-Amill L, Armand-Ugón M, Val-Casals M, et al. · Leukemia 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.